TScan Therapeutics(TCRX) - 2023 Q4 - Annual Results

Exhibit 99.1 TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE- C2 on HLA-B*07:02 and TSC-204-A0101 targetin ...